# The role of the gut microbiome-host metabolomeinteractions in heart failure-related insulin resistance

> **NIH NIH F32** · STANFORD UNIVERSITY · 2020 · $43,285

## Abstract

PROJECT SUMMARY / ABSTRACT
 Despite advances in management, heart failure (HF) is still associated with poor outcomes. Insulin resistance
is a common comorbidity in HF and independently portends worse outcomes. The mechanism by which insulin
resistance develops in HF has not been fully elucidated. Studies in subjects without HF have demonstrated
causal role of the gut microbiome in development of insulin resistance. Heart failure is associated with altered
gut microbiome, but it is not known how these changes in the microbiome affect the HF host metabolism and if
they increase the risk of developing insulin resistance. Because HF and insulin resistance share some gut
microbiome patterns, I hypothesize that the HF-related changes in the gut microbiome may contribute to
systemic metabolic changes that mediate insulin resistance in HF. I will test this hypothesis by defining gut
microbiome composition and concomitant metabolic profile in HF patients with and without insulin resistance.
 In Specific Aim 1, I will describe the gut microbiome patterns in HF patients in relation to their insulin
resistance. My hypothesis is that, compared to insulin-sensitive HF patients, insulin-resistant HF patients, will
have decreased gut microbial diversity, relative depletion of anti-inflammatory Lachnospiraceae, and enrichment
of the Prevotellaceae and Bacteroidaceae. By employing both 16S rRNA sequencing and shotgun metagenomic
sequencing, I will describe relative species abundance and relative gene abundance in the microbial community,
the latter of which will provide information about functional capacity of the microbiome. I will then examine
correlation between specific microbes/microbial gene clusters with clinical insulin resistance, in effort to identify
microbiomes and microbial gene clusters that may be contributing to insulin resistance.
 In Specific Aim 2, I will correlate the gut microbiome patterns to the serum metabolome in HF patients
stratified by insulin resistance. Insulin resistance is associated with elevated levels of serum branched chain
amino acids (BCAAs). Gut microbiota interact with the host through circulating metabolites, and, indeed, gut
commensals Prevotella copri and Bacteroides vulgatus have been shown to drive high levels of BCAAs in insulin
resistant states. I hypothesize that, compared to the insulin-sensitive HF patients, insulin-resistant HF patients
will have a distinct metabolic profile (e.g., higher levels of BCAAs) which will correlate with their gut microbial
signature (e.g., greater abundance of Prevotelaceae and Bacteroides). To test this hypothesis, I will characterize
the serum metabolome of the HF population described in Specific Aim 1 using a comprehensive clinical blood
panel and liquid chromatography-tandem mass spectrometry, then examine correlation between the
microbes/microbial gene clusters associated with insulin resistance in Aim 1, and specific metabolites.
 At the culmination of this project I will define ...

## Key facts

- **NIH application ID:** 9827492
- **Project number:** 5F32HL143916-02
- **Recipient organization:** STANFORD UNIVERSITY
- **Principal Investigator:** Petra Mamic
- **Activity code:** F32 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $43,285
- **Award type:** 5
- **Project period:** 2018-12-01 → 2021-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9827492

## Citation

> US National Institutes of Health, RePORTER application 9827492, The role of the gut microbiome-host metabolomeinteractions in heart failure-related insulin resistance (5F32HL143916-02). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/9827492. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
